Navigation Links
OGI invests in drug discovery at InDanio Bioscience
Date:10/19/2010

The InDanio screening system can be used, for example, to functionally characterize 'orphan' receptors those for which their natural ligands or specific function are unknown and thus qualify them as potential targets for drug discovery. The system can also be used to screen compound libraries in order to identify and refine potential new drugs that target NR proteins.

NRs are found inside cells and are responsible for sensing the presence of hormones and other molecules. They regulate the expression in the cell of a number of genes involved in homeostatic, metabolic and reproductive processes. NRs regulate the expression in the cell of a number of processes, and they also represent an important and successful class of drug targets implicated in some of the most prevalent diseases, including immune disorders, obesity, diabetes and cancer. A study four years ago determined that one seventh of drugs approved by the U.S. Food and Drug Administration (FDA) target nuclear receptors, and the top ten selling NR-based drugs combined represent worldwide annual sales of over USD $16 billion. Although many NRs have been targeted successfully, most of them have not been, and one third of them are still orphans.

InDanio was founded by Dr. Henry Krause, a professor in the Banting and Best Department of Medical Research at the University of Toronto, and Dr. Jens Tiefenbach, a post-doctoral fellow working with Dr. Krause and is based on the IP portfolio generated by their research.

"The OGI investment will allow InDanio to characterize the function of ill-understood members of the NR family and thus form the basis for establishing commercial partnerships to further characterize such receptors and develop drugs targeting them," commented Dr. Paul Chipperton, member of the InDanio board of directors and CEO of Profound Medical. "With a more efficient and comprehensive approach to probing the NR receptors, there is a tremendous opportunity to develop new therapeutic avenues into the NR family."

InDanio's zebrafish ligand trap (LT) technology and LT drug discovery platform will take advantage of the fact that zebrafish are transparent in early stages of development, thus allowing for the use of fluorescent protein markers. Many drugs never reach the marketplace because they fail toxicology tests or have other unintended effects on the body. Currently, in vitro testing relies on measuring simple chemical interactions to gauge a drug's effectiveness, but this is often not an effective predictor of how drugs will affect living organisms. By beginning the screening process with in vivo assays using live zebrafish, more information on a drug's effectiveness, toxicology and other side-effects can be gathered in advance of and to better inform downstream clinical trials.

"InDanio is in an excellent position to capitalize on the significant work undertaken by the academic and pharma sectors over the past 20 years in characterizing NR proteins and developing compound libraries targeting these proteins," commented Dr. Christian Burks, President and CEO of OGI. "Their screening system should provide novel, productive information on natural ligands, tissue and developmental specificity of natural or xenobiotic compounds, and whether or not a compound binds multiple receptors."


'/>"/>

Contact: Alastair Harris-Cartwright
aharriscartwright@ontariogenomics.ca
416-673-6582
Ontario Genomics Institute
Source:Eurekalert

Related biology news :

1. JPMorgan Chase & Co., Invests $25,000 to Support Bring Me A Books San Jose Elementary School Library Initiative
2. Finland invests €1.85 million in pan-European infrastructure for biomedical research
3. University of Plymouth invests in dental research
4. NIGMS invests in scientific Grand Opportunities with Recovery Act funds
5. Texas invests record $3.5 million in startup cofounded by UTs Mauro Ferrari
6. T cell discovery shows promise for Type 1 diabetes treatment: UBC-CFRI study
7. Research breakthrough hailed on the anniversary of gene discovery
8. Discovery of a cell that suppresses the immune system
9. Census of Marine Life celebrates decade of discovery
10. Discovery of key pathway interaction may lead to therapies that aid brain growth and repair
11. Biofuel from inedible plant material easier to produce following enzyme discovery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2016)... Elevay is currently known as ... for high net worth professionals seeking travel for work ... world, there is still no substitute for a face-to-face ... your deal with a firm handshake. This is why ... of citizenship via investment programs like those offered by ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting Medicaid ... setting a new clinical standard in telehealth thanks to ... leveraging the higi platform, IMPOWER patients can routinely track ... and body mass index, and, when they opt in, ... convenient visit to a local retail location at no ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... 27, 2016 , ... Parallel 6 , the leading software as a ... Reach Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine ... team. , Using the CONSULT module, patients and physicians can schedule a face to ...
(Date:6/27/2016)... BOSTON , June 27, 2016   Ginkgo ... biology to industrial engineering, was today awarded as ... a selection of the world,s most innovative companies. ... at scale for the real world in the ... organism engineers work directly with customers including Fortune ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles ... findings are the subject of a new article on the Surviving Mesothelioma website. ... blood, lung fluid or tissue of mesothelioma patients that can help point doctors to ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
Breaking Biology Technology: